Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

Cancer Treatment Reviews

Volumn 30, Issue 8, 2004, Pages 715-720

  Choti, Michael A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN ANTIBODY;

ADULT; ANALYTIC METHOD; ANALYTICAL ERROR; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG FATALITY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS;

EID: 8644249844     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.09.003     Document Type: Note

References (15)

1. D.M. Parkin F. Bray J. Ferlay P. Pisani Estimating the world cancer burden: Globocan 2000 Int J Cancer 15 94 2001 153-156
2. J.C. Weeks H. Nelson S. Gelber D. Sargent G. Schroeder Clinical Outcomes of Surgical Therapy (COST) Study Group Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs. open colectomy for colon cancer: A randomized trial JAMA 287 2002 321-328
3. M.S. Dunker W.A. Bemelman J.F. Slors P. van Duijvendijk D.J. Gouma Functional outcome, quality of life, body image, and cosmesis in patients after laparoscopic-assisted and conventional restorative proctocolectomy: A comparative study Dis Colon Rectum 44 2001 1800-1807
4. M.G. Tytherleigh N.J. McC Mortensen Options for sphincter preservation in surgery for low rectal cancer Br J Surg 90 2003 922-933
5. E. Kapiteijn C.A. Marijnen I.D. Nagtegaal et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638-646
6. M.A. Choti J.V. Sitzmann M.F. Tiburi et al. Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 235 2002 759-766
7. L.B. Saltz J.V. Cox C. Blanke et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905-914
8. A. de Gramont A. Figer M. Seymour et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938-2947
9. D. Cunningham Y. Humblet S. Siena et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337-345
10. N. Ferrara K.J. Hillan H.P. Gerber W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391-400
11. H. Nelson D.J. Sargent H.S. Wieand et al. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer N Engl J Med 350 2004 2050-2059
12. T. André C. Boni L. Mounedji-Boudiaf et al. Multicenter International Study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343-2351
13. C. Tournigand T. Andre E. Achille et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study J Clin Oncol 22 2004 229-237
14. H. Hurwitz L. Fehrenbacher W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335-2342
15. A.B. Benson M.A. Choti A.M. Cohen et al. National comprehensive cancer network. NCCN practice guidelines for colorectal cancer Oncology (Huntingt) 14 11A 2000 203-212